General Information of Drug (ID: DM7GNSY)

Drug Name
MEDI0618 Drug Info
Indication
Disease Entry ICD 11 Status REF
Osteoarthritis pain MG30.31 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DM7GNSY

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Imidazopyridazine derivative 8 DMF7NXJ Inflammation 1A00-CA43.1 Patented [3]
Piperazine urea derivative 4 DM3K7IM Inflammation 1A00-CA43.1 Patented [3]
Piperidine derivative 2 DMHXMB4 Inflammation 1A00-CA43.1 Patented [3]
Benzimidazole derivative 10 DML3PE4 N. A. N. A. Patented [3]
Benzothiazine-carboxamide compound 2 DMMP2RT Skin inflammation EF20.Y Patented [3]
Peptide analog 71 DMSEKZG N. A. N. A. Patented [3]
Amidine compound 3 DMV0QJ4 Inflammation 1A00-CA43.1 Patented [3]
Benzothiazine-carboxamide compound 4 DMSR918 Skin inflammation EF20.Y Patented [3]
Quinazoline derivative 11 DMAH435 Chronic obstructive pulmonary disease CA22 Patented [3]
PMID26936077-Compound-13 DMXK6LV Gastric ulcer DA60 Patented [3]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Proteinase activated receptor 2 (PAR2) TTQR74A PAR2_HUMAN Antagonist [2]

References

1 ClinicalTrials.gov (NCT05714254) A Randomised, Double-blind, Placebo-controlled Study of the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of MEDI0618 in Healthy Male and Female Volunteers. U.S.National Institutes of Health.
2 Clinical pipeline report, company report or official report of AstraZeneca
3 Protease activated receptor 2 (PAR2) modulators: a patent review (2010-2015).Expert Opin Ther Pat. 2016;26(4):471-83.